Alpha 2.0
Login Register
» Authors » Mario Nardi

Mario Nardi

Explore the profile of Mario Nardi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 142
Followers 0
Related Specialties
Oncology
General Surgery
Infectious Diseases
Top 10 Co-Authors
Roberto Maisano
Stefano Cascinu
Salvatore Palazzo
Antonino Mafodda
Giovanni Egitto
Giampietro Gasparini
Marzia Mare
Maria Bottari
Stefano Molica
Maurizio Maisano
Published In
Tumori
Anticancer Res
BMC Cancer
Cancer Chemother Pharmacol
Head Neck
Affiliations
Soon will be listed here.
Recent Articles
1.
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel
Maison-Blanche P, Vermorken J, Goksel T, Machiels J, Agarwala S, Rottey S, et al.
J Cardiovasc Pharmacol . 2013 Feb; 61(6):495-504. PMID: 23429593
: The effect of repeated doses of aflibercept on ventricular repolarization in cancer patients was evaluated in an intensive electrocardiogram trial. This randomized, placebo-controlled, double-blind trial was conducted in 87...
2.
Mucinous histology of colon cancer predicts poor outcomes with FOLFOX regimen in metastatic colon cancer
Maisano R, Azzarello D, Maisano M, Mafodda A, Bottari M, Egitto G, et al.
J Chemother . 2012 Oct; 24(4):212-6. PMID: 23040685
Mucinous adenocarcinoma (MA) of colorectal cancer seems associated with reduced responsiveness to chemotherapy. The overexpression of markers of resistance to fluorouracil and oxaliplatin has recently been demonstrated. We revised the...
3.
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer
Grossi F, de Marinis F, Gebbia V, Riccardi F, Caffo O, Gamucci T, et al.
Cancer Chemother Pharmacol . 2011 Aug; 69(2):369-75. PMID: 21833588
Purpose: The aim of this study was to determine the activity and toxicity of two sequential chemotherapy regimens in the first-line treatment of advanced non-small-cell lung cancer (NSCLC). Methods: Eighty-eight...
4.
Alkaline phosphatase levels as a prognostic factor in metastatic colorectal cancer treated with the FOLFOX 4 regimen: a monoinstitutional retrospective study
Maisano R, Azzarello D, Del Medico P, Maisano M, Bottari M, Egitto G, et al.
Tumori . 2011 May; 97(1):39-42. PMID: 21528662
Aims And Background: Metastatic colorectal cancer has a heterogeneous behavior, and a set of patients will have minimal response and rapid disease progression. To understand this heterogeneity, studies have evaluated...
5.
Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer
Novello S, Falcone A, Crino L, Rinaldi M, Nardi M, de Marinis F, et al.
Lung Cancer . 2009 Mar; 66(3):327-32. PMID: 19329221
Background: In the attempt to optimize the efficacy of chemotherapy in advanced non-small cell lung cancer (NSCLC) several strategies need to be investigated including the use of non-platinum combinations and...
6.
Mitomycin C plus capecitabine (mixe) in anthracycline- and taxane-pretreated metastatic breast cancer. A multicenter phase II study
Maisano R, Caristi N, Mare M, Raffaele M, Iorfida M, Mafodda A, et al.
Anticancer Res . 2007 Aug; 27(4C):2871-5. PMID: 17695463
Background: Capecitabine is considered the treatment of choice for anthracycline- and taxane-pretreated metastatic breast cancer. Mitomycin C seems to improve the activity of capecitabine by up-regulation of thymidine phosphorylase. Patients...
7.
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial
Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A, et al.
J Natl Cancer Inst . 2007 Apr; 99(8):601-7. PMID: 17440161
Background: Promising findings obtained using a weekly regimen of 5-fluorouracil (5-FU), epidoxorubicin, leucovorin (LV), and cisplatin (PELFw) to treat locally advanced and metastatic gastric cancer prompted the Italian Group for...
8.
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study
Pignata S, De Placido S, Biamonte R, Scambia G, Di Vagno G, Colucci G, et al.
BMC Cancer . 2006 Jan; 6:5. PMID: 16398939
Background: Carboplatin/paclitaxel is the chemotherapy of choice for advanced ovarian cancer, both in first line and in platinum-sensitive recurrence. Although a significant proportion of patients have some neurotoxicity during treatment,...
9.
Mitomycin C and capecitabine combination (MiXe) in heavily pretreated metastatic breast cancer patients. A dose-finding study
Maisano R, Caristi N, Mare M, Mafodda A, Carboni R, Montalto E, et al.
Anticancer Res . 2005 Dec; 25(6C):4513-7. PMID: 16334135
Background: No standard chemotherapy has been defined for metastatic breast cancer patients pretreated with anthracyclines and taxanes. In preclinical studies, mitomycin C (MMC) and capecitabine showed a synergistic effect by...
10.
Long-term survival in locally advanced oral cavity cancer: an analysis of patients treated with neoadjuvant cisplatin-based chemotherapy followed by surgery
Ruggeri E, Carlini P, Pollera C, De Marco S, Ruscito P, Pinnaro P, et al.
Head Neck . 2005 May; 27(6):452-8. PMID: 15880411
Background: Neoadjuvant chemotherapy has been reported to be extremely active in head and neck cancer but has failed to give a statistically significant improvement in survival. Methods: From 1981 to...